Jane Street Group LLC Boosts Stock Holdings in Mesoblast Limited (NASDAQ:MESO)

Jane Street Group LLC increased its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 46.4% during the third quarter, HoldingsChannel.com reports. The firm owned 85,102 shares of the company’s stock after buying an additional 26,959 shares during the period. Jane Street Group LLC’s holdings in Mesoblast were worth $695,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. XY Capital Ltd purchased a new position in shares of Mesoblast in the 3rd quarter worth about $244,000. Signaturefd LLC raised its stake in shares of Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after acquiring an additional 3,099 shares during the last quarter. Creative Planning purchased a new position in shares of Mesoblast during the third quarter valued at approximately $147,000. Perkins Coie Trust Co raised its holdings in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Lazari Capital Management Inc. lifted its holdings in Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after buying an additional 3,300 shares during the period. 1.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on MESO. Piper Sandler boosted their price target on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Tuesday, September 24th. Finally, Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.50.

Mesoblast Stock Performance

NASDAQ:MESO opened at $20.12 on Friday. Mesoblast Limited has a fifty-two week low of $1.61 and a fifty-two week high of $22.00. The stock’s fifty day moving average is $12.36 and its 200 day moving average is $9.09. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.